ClinicalTrials.gg
RecruitingNCT07263191Updated Dec 4, 2025

A Study of Olanzapine in Participants With Bipolar Disorder.

An observational study in Bipolar Disorder, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Boryung Pharmaceutical Co., Ltd · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 28 studies in Bipolar Disorder with a site in Korea, Republic of — 4 open to participants now, 4 under way, 1 of them phase 3. Bipolar Disorder · Korea, Republic of.

Started
2025
with 1 other
Observational
9 of 28
3 open now
Registered
26th of 28
by date
Lead sponsor
1 of 28
Boryung Pharmaceutical Co., Ltd

Among the 28 studies in Bipolar Disorder with a site in Korea, Republic of, this one is one of 2 that started in 2025, is one of 9 observational ones, and was the 26th registered.

Bipolar Disorder

1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

4 of the 28 studies in Bipolar Disorder with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Bipolar Disorder with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Olanzapine
  • Observation study
  • Bipolar Disorder
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with bipolar disorder who require olanzapine administration

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have signed the after receiving information about the purpose and method of this study.
  • Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.
  • Patients who understand the contents of the survey and can answer the questions directly.

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant, have , or are breastfeeding.
  • Has received an product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
  • Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Interventions

  • As this is a non-interventional study designed to collect data as part of routine clinical practice, the selection and dosage of medication, treatment period, and whether or not to change it are all based on the clinician's judgment.

06

What researchers measure

Primary outcomes

  1. Treatment pattern

    Frequency and percentage of the therapeutic class of bipolar disorder agents administered within 8 weeks prior to baseline will be presented based on the patients' demographic factors and clinical characteristics. Furthermore, frequency and percentage of the therapeutic class patterns of bipolar disorder agents administered after baseline will be presented

    Time frame: Baseline, 8weeks, 12weeks

Secondary outcomes

  1. Change From Baseline in Young Mania Rating Scale (YMRS) Score at 8 Weeks and 12Weeks.

    The YMRS scoring system ranges from 0 (no symptoms) to 4 or 8 (severe symptoms)

    Time frame: Baseline, 8weeks, 12weeks

  2. Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Score at 8 Weeks and 12Weeks.

    The PHQ-9 scoring system ranges from 0 to 27, with higher scores indicating more severe depression. Each item is scored on a scale from 0 to 3

    Time frame: Baseline, 8weeks, 12weeks

  3. Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at 8 Weeks and 12Weeks.

    The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses from 0 (not assessed) through to 7 (amongst the most severely ill patients).

    Time frame: Baseline, 8weeks, 12weeks

  4. Clinical Global Impression Scale-Improvement (CGI-I) scores at 8 and 12 weeks after drug administration

    The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses from 0 (not assessed) through to 7 (amongst the most severely ill patients).

    Time frame: Baseline, 8weeks, 12weeks

  5. Adverse events

    Time frame: Up to 27months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 105 observational studies under Bipolar Disorder, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 118. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2025
First posted
Dec 4, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07263191
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Oct 30, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Shinyoung Oh
Contact
syoh@boryung.co.kr
+82 2-708-8000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion